Profile data is unavailable for this security.
About the company
Ironwood Pharmaceuticals, Inc. is a gastrointestinal (GI) healthcare company engaged in advancing the treatment of GI diseases and redefining the standard of care for GI patients. It is engaged in the development of LINZESS (linaclotide) for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). Linaclotide is also approved for the treatment of functional constipation in pediatric patients ages 6-17 years old. It is advancing apraglutide, a long-acting synthetic glucagon-like peptide-2 (GLP-2) analog being developed for rare gastrointestinal diseases, including short bowel syndrome with intestinal failure (SBS-IF) as well as several earlier stage assets. It is advancing IW-3300, a GC-C agonist, for the potential treatment of visceral pain conditions, such as interstitial cystitis/bladder pain syndrome (IC/BPS), and endometriosis. It is also developing CNP-104 for the treatment of PBC, a rare autoimmune disease targeting the liver.
- Revenue in USD (TTM)442.74m
- Net income in USD-1.00bn
- Incorporated1998
- Employees267.00
- LocationIronwood Pharmaceuticals Inc100 Summer Street, Suite 2300BOSTON 02110United StatesUSA
- Phone+1 (617) 621-7722
- Fax+1 (617) 494-0480
- Websitehttps://www.ironwoodpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | IRWD:NSQ since announced | Transaction value |
|---|---|---|
| VectivBio Holding AG | -22.54% | 1.15bn |
Data delayed at least 15 minutes, as of May 06 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MannKind Corp | 198.96m | -11.94m | 1.19bn | 414.00 | -- | -- | -- | 5.99 | -0.0464 | -0.0464 | 0.7087 | -0.9116 | 0.5165 | 2.50 | 12.55 | 480,584.50 | -3.10 | -26.07 | -3.99 | -37.80 | 68.45 | 59.68 | -6.00 | -57.61 | 3.31 | 0.5023 | 1.90 | -- | 99.42 | 48.17 | 86.34 | -- | 160.47 | -- |
| Scholar Rock Holding Corp | 0.00 | -165.79m | 1.20bn | 150.00 | -- | 5.08 | -- | -- | -1.99 | -1.99 | 0.00 | 2.96 | 0.00 | -- | -- | 0.00 | -49.55 | -38.14 | -55.26 | -44.31 | -- | -- | -- | -647.95 | -- | -- | 0.1817 | -- | -100.00 | -- | -23.26 | -- | -45.61 | -- |
| AbCellera Biologics Inc | 38.03m | -146.40m | 1.21bn | 586.00 | -- | 1.04 | -- | 31.77 | -0.5062 | -0.5062 | 0.1315 | 3.96 | 0.0251 | -- | 1.10 | 64,890.79 | -9.67 | 6.08 | -10.49 | 6.67 | -- | -- | -384.99 | 24.69 | 7.32 | -- | 0.00 | 0.00 | -92.17 | 33.91 | -192.35 | -- | 70.96 | -- |
| Collegium Pharmaceutical Inc | 566.77m | 48.16m | 1.21bn | 197.00 | 41.96 | 6.04 | 6.13 | 2.14 | 0.8823 | 0.8823 | 12.53 | 6.13 | 0.4891 | 6.10 | 3.13 | 2,876,990.00 | 4.16 | 2.79 | 6.75 | 4.80 | 57.55 | 50.88 | 8.50 | 5.16 | 1.10 | 2.59 | 0.7734 | 0.00 | 22.17 | 15.11 | 292.60 | -- | -54.77 | -- |
| Pharvaris NV | 0.00 | -108.62m | 1.22bn | 82.00 | -- | 2.87 | -- | -- | -2.72 | -2.72 | 0.00 | 7.91 | 0.00 | -- | -- | 0.00 | -35.62 | -36.09 | -37.81 | -38.27 | -- | -- | -- | -- | -- | -33.51 | 0.0006 | -- | -- | -- | -32.15 | -- | -- | -- |
| Cullinan Therapeutics Inc | 0.00 | -153.16m | 1.22bn | 85.00 | -- | 2.69 | -- | -- | -3.70 | -3.70 | 0.00 | 10.58 | 0.00 | -- | -- | 0.00 | -29.68 | -12.37 | -31.19 | -12.93 | -- | -- | -- | -1,026.78 | -- | -- | 0.00 | -- | -- | -- | -237.72 | -- | -4.44 | -- |
| Pacira Biosciences Inc | 674.98m | 41.96m | 1.23bn | 711.00 | 39.04 | 1.42 | 10.48 | 1.83 | 0.6789 | 0.6789 | 12.33 | 18.72 | 0.4147 | 1.84 | 6.62 | 949,336.10 | 2.58 | 3.35 | 2.79 | 3.98 | 72.64 | 72.63 | 6.22 | 8.57 | 4.17 | 9.85 | 0.3752 | 0.00 | 1.22 | 14.88 | 163.72 | -- | 0.8761 | -- |
| Mirum Pharmaceuticals Inc | 186.37m | -163.42m | 1.24bn | 264.00 | -- | 4.96 | -- | 6.67 | -4.08 | -4.08 | 4.56 | 5.32 | 0.3729 | 3.37 | 4.05 | 705,962.10 | -32.70 | -38.93 | -38.55 | -44.88 | 74.76 | -- | -87.68 | -190.71 | 4.19 | -79.67 | 0.552 | -- | 141.85 | -- | -20.45 | -- | 21.81 | -- |
| Gyre Therapeutics Inc | 0.00 | -44.24m | 1.27bn | 7.00 | -- | -- | -- | -- | -20.60 | -20.60 | 0.00 | 1.39 | 0.00 | -- | -- | 0.00 | -215.90 | -58.25 | -235.61 | -72.12 | -- | -- | -- | -817.06 | -- | -- | 0.00 | -- | -89.18 | -4.85 | 90.63 | -- | -- | -- |
| Prothena Corporation PLC | 91.37m | -147.03m | 1.28bn | 173.00 | -- | 2.27 | -- | 13.96 | -2.80 | -2.80 | 1.68 | 10.46 | 0.1256 | -- | -- | 528,150.30 | -20.22 | -14.20 | -21.82 | -15.11 | -- | -- | -160.92 | -111.02 | -- | -- | 0.00 | -- | 69.50 | 148.98 | -25.72 | -- | 9.71 | -- |
| Ironwood Pharmaceuticals, Inc. | 442.74m | -1.00bn | 1.29bn | 267.00 | -- | -- | -- | 2.91 | -6.51 | -6.51 | 2.59 | -2.21 | 0.5634 | -- | 3.62 | 1,658,184.00 | -131.28 | -4.54 | -162.45 | -5.20 | -- | -- | -233.00 | -7.81 | -- | 63.79 | 1.98 | -- | 7.83 | 5.02 | -672.50 | -- | 160.10 | -- |
| Ligand Pharmaceuticals Inc | 131.31m | 53.82m | 1.31bn | 58.00 | 25.06 | 1.82 | 14.48 | 9.96 | 2.91 | 2.81 | 7.26 | 39.92 | 0.1695 | 0.5642 | 4.15 | 2,264,035.00 | 6.94 | 12.32 | 7.50 | 12.99 | 91.99 | 81.65 | 40.98 | 80.32 | 12.72 | -- | 0.00001 | -- | -33.09 | -12.18 | 1,131.21 | -17.86 | 42.63 | -- |
| Spyre Therapeutics Inc | 886.00k | -338.79m | 1.31bn | 30.00 | -- | -- | -- | 1,477.62 | -75.04 | -75.04 | 0.1285 | 7.45 | 0.0043 | -- | 4.73 | 29,533.33 | -164.06 | -101.87 | -184.94 | -118.83 | -- | -- | -38,238.15 | -2,949.59 | -- | -- | 0.00 | -- | -61.96 | -25.61 | -304.21 | -- | -- | -- |
| Belite Bio Inc (ADR) | 0.00 | -31.63m | 1.32bn | 20.00 | -- | 13.96 | -- | -- | -1.24 | -1.24 | 0.00 | 3.10 | 0.00 | -- | -- | 0.00 | -45.54 | -- | -47.50 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -150.09 | -- | -- | -- |
| 4D Molecular Therapeutics Inc | 20.72m | -100.84m | 1.37bn | 147.00 | -- | 3.74 | -- | 66.06 | -2.58 | -2.58 | 0.5438 | 7.15 | 0.0689 | -- | -- | 140,972.80 | -33.52 | -32.67 | -35.57 | -34.90 | -- | -- | -486.59 | -617.15 | -- | -- | 0.00 | -- | 562.29 | 7.96 | 6.19 | -- | 46.26 | -- |
Data as of May 06 2024. Currency figures normalised to Ironwood Pharmaceuticals Inc's reporting currency: US Dollar USD
61.68%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 23.05m | 14.73% |
| Sarissa Capital Management LPas of 15 Mar 2024 | 16.39m | 10.47% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 15.71m | 10.04% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 11.53m | 7.37% |
| LSV Asset Managementas of 31 Dec 2023 | 6.78m | 4.33% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 6.60m | 4.21% |
| Armistice Capital LLCas of 31 Dec 2023 | 5.70m | 3.64% |
| Credit Suisse International (Investment Management)as of 31 Dec 2023 | 4.00m | 2.56% |
| Brown Capital Management LLCas of 31 Dec 2023 | 3.71m | 2.37% |
| Dimensional Fund Advisors LPas of 31 Dec 2023 | 3.08m | 1.97% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
